• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

46.13 -0.04 (-0.09%)
Official Closing Price Updated: 7:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,995,606
Open 46.59
Bid (Size) 44.53 (200)
Ask (Size) 52.50 (100)
Prev. Close 46.17
Today's Range 45.97 - 46.75
52wk Range 32.53 - 57.81
Shares Outstanding 227,985,334
Dividend Yield 0.76%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
October 13, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys? ↗
October 12, 2026
Forget the "Magnificent Seven" in favor of the "Tremendous Three"? 
Via The Motley Fool

Performance

52-Week Range 20.2% below 52-week high
46.13
32.5352W Low 57.8152W High
1 Week 1.3% below 1-week high
44.951W Low 46.751W High

Qiagen N.V. Common Shares (QGEN) traded between $32.53 and $57.81 over the past 52 weeks and last traded at $46.13, 20.2% below its 52-week high. Over the past week it ranged between $44.95 and $46.75.

Past 12 Months
+1.8%
+7.5%
+12.1%
+11.9%
+2.1%
-4.2%
1W +$0.82
1M +$3.23
3M +$4.98
6M +$4.89
YTD +$0.94
1Y -$2.00

QGEN was -4.2% over the past year, +11.9% over six months, +2.1% year to date, +1.8% in the last week.

12 Months vs Market
QGEN
-4.2%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months QGEN returned -4.2% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.81× 3-mo avg
Today 1,995,606 3-mo avg 2.5M
1W
1.5M
1M
2.2M
3M
2.5M
6M
2.6M
YTD
2.5M
1Y
2.2M

QGEN most recently traded 1,995,606 shares against a 3-month average daily volume of 2.5M.

More News

Read More
News headline image
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
October 06, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
September 28, 2026
From QIAGEN N.V.
Via Business Wire
QIAGEN (NYSE:QGEN) Eyes Breakout With Technical Rating 7 and Setup Rating 9 ↗
September 24, 2026
Via Chartmill
News headline image
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
September 24, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
September 18, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
August 27, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
August 24, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen (QGEN) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings Immigration
News headline image
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
August 10, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Q2 Earnings Call Highlights ↗
August 08, 2026
Via MarketBeat
Topics Earnings Immigration
News headline image
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
August 05, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
July 15, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
July 15, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
July 14, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
June 15, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
May 28, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
May 21, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
May 20, 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
May 19, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
May 19, 2026
From QIAGEN N.V.
Via Business Wire

Frequently Asked Questions

Is Qiagen N.V. Common Shares publicly traded?
Yes, Qiagen N.V. Common Shares is publicly traded.
What exchange does Qiagen N.V. Common Shares trade on?
Qiagen N.V. Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Qiagen N.V. Common Shares?
The ticker symbol for Qiagen N.V. Common Shares is QGEN on the New York Stock Exchange
What is the current price of Qiagen N.V. Common Shares?
The current price of Qiagen N.V. Common Shares is 46.13
When was Qiagen N.V. Common Shares last traded?
The last trade of Qiagen N.V. Common Shares was at 10/16/26 07:00 PM ET
What is the market capitalization of Qiagen N.V. Common Shares?
The market capitalization of Qiagen N.V. Common Shares is 10.52B
How many shares of Qiagen N.V. Common Shares are outstanding?
Qiagen N.V. Common Shares has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap